(untitled) - Ahmann, A; Capehorn, M; Charpentier, G
et al. Efficacy and safety of onceweekly semaglutide vs. exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes 2016; 65 (Suppl. 1): 187-OR